6/28/23, 11:51 PM JUPITER Pathway Feedback Search Clinical Topics Home Studies JUPITER JUPITER Disease Disease Disease Acute ischemic stroke Non-ST-elevation myocardial inf ST-elev Trial question What is the role of rosuvastatin in preventing vascular events among healthy men and women with elevated CRP? Study design Multi-center Double blinded RCT Population Characteristics of study participants 38.0% female N = 17802 62.0% male 17802 patients (6801 female, 11001 male) Inclusion criteria: healthy men and women with low-density lipoprotein (LDL) cholesterol levels < 130 mg/dL and hs-CRP levels 2.0 mg/L Key exclusion criteria: previous or current use of lipid-lowering therapy, current use of postmenopausal hormone-replacement therapy, evidence of hepatic dysfunction, diabetes, uncontrolled hypertension, uncontrolled hypothyroidism, and a recent history of alcohol or drug abuse Interventions N=8901 rosuvastatin (20 mg daily) N=8901 placebo (matching placebo daily) Primary outcome https://web.pathway.md/studies/rectkXYfMeBjURIsS 1/2 6/28/23, 11:51 PM JUPITER Pathway Myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes 1.4 1.36 1.0 0.77 0.7 0.3 Significant decrease 0.0 Rosuvastatin Placebo Significant decrease in myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes (0.77 vs. 1.36; HR 0.56, 95% CI 0.46 to 0.69) Secondary outcomes Significant decrease in myocardial infarction (0.17 vs. 0.37; HR 0.46, 95% CI 0.3 to 0.7) Significant decrease in stroke (0.18 vs. 0.34; HR 0.52, 95% CI 0.34 to 0.79) Significant decrease in myocardial infarction, stroke, or death from cardiovascular causes (0.45 vs. 0.85; HR 0.53, 95% CI 0.4 to 0.69) Safety outcomes No significant differences in serious adverse events (15.2% vs. 15.5%, p=0.60), myopathy (0.1% vs. 0.1%, p=0.82) or cancer (3.4% vs. 3.5%, p=0.51). Significant differences in physician-reported diabetes (3.0% vs. 2.4%, p = 0.01). Conclusion In healthy men and women with low-density lipoprotein (LDL) cholesterol levels < 130 mg/dL and hs-CRP levels 2.0 mg/L, rosuvastatin was superior to placebo with respect to myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. Reference Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. Open reference URL https://web.pathway.md/studies/rectkXYfMeBjURIsS 2/2